FDA starter doses vs compounded microdose plans: price and what the labels allow
Released: · Last reviewed:
The lowest FDA-labeled doses cost $149 to $349 a month self-pay in November 2026: the Wegovy pill at 1.5 mg and Foundayo at 0.8 mg are $149, Zepbound's 2.5 mg vials or KwikPen $299, and Wegovy's 0.25 mg pen $349. Those labels treat the starting dose as a step toward maintenance, not a place to stay.
People who want a "microdose" often ask a sensible question: why not just buy the lowest approved dose of the real thing? The approved products are FDA-reviewed, made in inspected plants and sold at published self-pay prices. This article puts the lowest labeled dose of four brands next to the compounded microdose plans we track, and reads what each label says about staying low.
The lowest labeled dose of each brand, and what the label says about it
| Product | Starting dose | How long | Labeled maintenance dose | What the label says about the starting dose |
|---|---|---|---|---|
| Zepbound (tirzepatide injection) | 2.5 mg weekly | 4 weeks, then 5 mg | 5, 10 or 15 mg weekly | "The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage." |
| Wegovy (semaglutide injection) | 0.25 mg weekly | 4 weeks, then 0.5, 1 and 1.7 mg | 1.7 or 2.4 mg weekly (2.4 recommended; up to 7.2 mg) | No separate sentence; 0.25 mg is listed only as the first escalation step |
| Wegovy pill (oral semaglutide) | 1.5 mg daily | 30 days, then 4 and 9 mg | 25 mg daily (the only maintenance dose) | No separate sentence; 1.5 mg is the first of four escalation steps |
| Foundayo (orforglipron tablet) | 0.8 mg daily | At least 30 days, then 2.5 and 5.5 mg | No specific maintenance dose named; up to 17.2 mg | No separate sentence; doses above 5.5 mg depend on response and tolerability |
Only Zepbound's label says in so many words that its starting dose is not a maintenance dose. The other three get there by structure: each lists the starting dose as the first rung of a ladder with a set time on it. The labels do allow some flexibility for side effects. Wegovy's says that if a dose is not tolerated during escalation, prescribers can "consider delaying dosage escalation for 4 weeks," and Zepbound's says, "If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage." That lower maintenance option is 5 mg, not 2.5 mg.
What the lowest labeled dose costs
| Option | Price per month | What a month contains | Source · date |
|---|---|---|---|
| Wegovy pill 1.5 mg | $149 | 30 tablets | NovoCare · Nov 8, 2026 |
| Foundayo 0.8 mg | $149 | 30 days | LillyDirect (archived Oct 29, 2026) |
| Zepbound 2.5 mg, vials or KwikPen | $299 | 4 single-dose vials or 1 KwikPen (4 doses), 28 days | Lilly · Nov 8, 2026 |
| Wegovy pen 0.25 mg | $349 ($199 for two fills if new to the offer, through Dec 31, 2026) | 4 pens | NovoCare · Nov 8, 2026 |
| Compounded microdose semaglutide, median of 7 programs | $99 | Dose set by prescriber | Programs' own pages · Nov 8, 2026 |
| Compounded microdose tirzepatide, median of 6 programs | $149 | Dose set by prescriber | Programs' own pages · Nov 8, 2026 |
| NexLife microdose semaglutide / tirzepatide | $109 / $129 ($95 / $115 on 12 months) | Dose set by prescriber | nexlife.us · Nov 8, 2026 |
Lilly's site blocked automated reading on November 8, so Foundayo's figures come from the LillyDirect page as archived on October 29, 2026. That page also says the 2.5 mg and 5.5 mg prices are "temporarily reduced through December 31, 2026" ($149 and $199); Lilly's savings page gives the regular prices as $199 and $299. The 0.8 mg price is $149 either way.
Worked examples: six months at a low dose
Staying on Zepbound 2.5 mg for six months would cost 6 × $299 = $1,794, and it would mean using a dose the label says is not approved for maintenance. Moving up on schedule changes the bill: one month at 2.5 mg ($299), one at 5 mg ($399) and four at 7.5 mg with on-time refills (4 × $449) comes to $2,494.
Starting Wegovy's pen if you are new to the offer: two months at the $199 intro price, then four at $349, is 2 × $199 + 4 × $349 = $1,794 for six months, the same figure as Zepbound's 2.5 mg by coincidence. The pen price does not change between 0.25 mg and 2.4 mg, so climbing the ladder costs nothing extra.
Wegovy pill on the label's schedule: one month each at 1.5 mg ($149), 4 mg ($199) and 9 mg ($299), then three months at 25 mg (3 × $299), totals $1,544. Holding at 1.5 mg would be 6 × $149 = $894, but 1.5 mg is a starting step, not a labeled maintenance dose.
A compounded microdose plan: NexLife's 6-month semaglutide plan is 6 × $99 = $594, and its tirzepatide plan 6 × $119 = $714. Good Girl Rx's 6-month semaglutide plan is 6 × $86 = $516, paid up front. These are cheaper than any brand route above, but the product is not FDA-approved and no trial has tested it at a microdose.
How small is a microdose compared with a starting dose?
Most compounded programs do not print their doses, so a straight comparison is only possible for a few. Noom's chart for compounded semaglutide runs from 0.2 mg to a 0.6 mg weekly maximum. Wegovy starts at 0.25 mg and steps to 0.5 mg after four weeks, so Noom's whole range sits around Wegovy's first two steps. Lemonaid caps its microdoses at "25% of the standard maintenance dose." For semaglutide, 25% of Wegovy's recommended 2.4 mg is 0.6 mg, which matches Noom's ceiling. For tirzepatide the answer depends on which maintenance dose counts as standard: 25% of 5 mg is 1.25 mg and 25% of 15 mg is 3.75 mg, which straddles Zepbound's 2.5 mg starting dose.
Per milligram, brand starting doses are expensive. Zepbound 2.5 mg weekly is 10 mg per 28 days for $299, about $29.90 per mg; at 15 mg weekly, 60 mg costs $449 with on-time refills, about $7.48 per mg. A Wegovy pen month at 0.25 mg holds 1 mg for $349. Compounded programs that charge one price at every dose follow the same logic: the lower your dose, the more you pay per milligram.
Insurance and Medicare
Coverage follows the labeled products, not microdoses. The Medicare GLP-1 Bridge, which charges $50 for a one-month supply, covers Foundayo, Wegovy (injection or tablet) and the Zepbound KwikPen only, not Zepbound single-dose vials or pens, and only for people who meet its BMI and condition criteria. Per Medicare.gov, people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge, though their Part D plan "might cover" a GLP-1. No compounded product is covered. Lilly's Zepbound KwikPen savings offer for self-pay buyers allows 11 fills a calendar year, and its savings end December 31, 2026.
Side effects: the real reason many people ask
Most people looking for a microdose are trying to avoid nausea and other stomach side effects rather than save money. The labels handle that through the pace of escalation, not through a permanent low dose. Wegovy's label tells prescribers that if two or more doses in a row are missed, they should restart escalation at a lower dose "to reduce the risk of gastrointestinal adverse reactions," and it allows a four-week pause before the next step when a dose is not tolerated. Zepbound's label sets at least four weeks between increases and lets prescribers settle on a lower maintenance dose. Foundayo's label ties every step above 5.5 mg to response and tolerability. In other words, the approved route already has a built-in way to go slowly. Ask about it before you decide that a compounded microdose is the only gentle option, and tell your prescriber what you have tried.
Why a brand pen cannot deliver a microdose
The brand devices are built around fixed doses. Zepbound comes as single-dose pens and vials in six strengths from 2.5 mg to 15 mg, a KwikPen that delivers four fixed doses, and a newer multi-dose vial holding four doses. Wegovy's single-dose pens come in 0.25, 0.5, 1, 1.7, 2.4 and 7.2 mg, and its FlexTouch pen delivers four 2.4 mg doses. The tablets come in fixed strengths too. None of the labels gives directions for taking part of a dose, and the Wegovy label warns never to share a FlexTouch pen between patients. So the smallest amount you can take of an approved product, as labeled, is its starting dose. Anything smaller means a compounded product or an off-label workaround with a device that was not designed for it, which raises the risk of dosing errors. If a smaller dose is what you want, that is a conversation for your prescriber, not a do-it-yourself project with a pen.
What this means for you
- If you want an FDA-approved product, the lowest self-pay price is a pill: the Wegovy pill at 1.5 mg or Foundayo at 0.8 mg, both $149 a month. Expect your prescriber to move you up the ladder.
- Staying on a starting dose is an off-label decision for your prescriber. Zepbound's label says 2.5 mg is not approved for maintenance; its lowest maintenance dose is 5 mg.
- If side effects are the worry, ask about slower escalation, which the Wegovy label allows, before switching to a compounded microdose.
- If you choose a compounded microdose plan, it will usually cost less than the brand routes, but ask for the dose in milligrams and the pharmacy's name, and know that it is not FDA-approved.
- Prices on the brand side change on January 1 if the year-end offers are not renewed; recheck in December.
More: low dose vs microdose, microdose plan prices, November 2026, tirzepatide cost, semaglutide cost and maintenance.
Editor's pick · 94/100 on our v4.1 rubric
If you choose a compounded microdose: our #1 pick, NexLife
- Microdose tirzepatide: $129 a month month to month, or $125 / $119 / $115 a month on 3-, 6- or 12-month plans ($1,380 for a 12-month plan), as of November 8, 2026.
- Microdose semaglutide: $109 a month month to month, or $105 / $99 / $95 ($1,140 for 12 months), as of November 8, 2026.
- One price covers the medication, provider review through NexLife Medical Group, a nutrition plan, a coaching call and shipping; no membership fee; same price at every dose.
- Its standard plan pages name three state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA).
Microdose tirzepatide plans → Microdose semaglutide plans → Read the NexLife review
Compounded tirzepatide and semaglutide are not FDA-approved. A prescription requires a clinician's review; prices are NexLife's own published figures.
Frequently asked questions
Is the Zepbound 2.5 mg dose a microdose?
It is the labeled starting dose, used for four weeks before moving to 5 mg. Zepbound’s label says it "is for treatment initiation and is not approved as a maintenance dosage." Staying on it long term is an off-label choice for a prescriber.
What is the cheapest FDA-approved GLP-1 starting dose?
In November 2026, the Wegovy pill at 1.5 mg (NovoCare) and Foundayo at 0.8 mg (LillyDirect, archived October 29) are both $149 a month self-pay. Zepbound 2.5 mg is $299 and the Wegovy pen $349, or $199 for two intro fills for new patients through December 31, 2026.
Is a compounded microdose cheaper than a brand starting dose?
Usually. The median compounded microdose plan in our November 8 index costs $99 a month for semaglutide and $149 for tirzepatide, against $149 to $349 for brand starting doses. The compounded product is not FDA-approved.
Can I stay on a starting dose to keep costs down?
That is a decision for your prescriber, and an off-label one for Zepbound 2.5 mg. The Wegovy pen costs the same at every dose from 0.25 to 2.4 mg, so staying low saves nothing there.
Does Medicare cover a microdose?
No. The Medicare GLP-1 Bridge covers Foundayo, Wegovy and the Zepbound KwikPen at labeled doses for eligible people, at $50 a month. It does not cover compounded products or Zepbound vials.
Sources
- Zepbound prescribing information (Lilly, rev. 08/2026) — read November 8, 2026
- Wegovy injection and tablets prescribing information (Novo Nordisk, rev. 06/2026) — read November 8, 2026
- Foundayo prescribing information (Lilly, rev. 07/2026) — read November 8, 2026
- Zepbound coverage and savings (Lilly) — read November 8, 2026
- LillyDirect Foundayo self-pay page — archived October 29, 2026
- NovoCare — Wegovy self-pay pricing — read November 8, 2026
- Medicare.gov — GLP-1 drugs for weight loss (GLP-1 Bridge) — read November 8, 2026
- Noom Med — microdose dosing guide — read November 8, 2026
- Lemonaid Health — compounded semaglutide microdoses — read November 8, 2026
- NexLife — microdose semaglutide program — read November 8, 2026
Not medical advice. Compounded semaglutide and tirzepatide are not FDA-approved and are not the same products as Wegovy or Zepbound. Talk with a licensed clinician about your situation.